Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

Annals of Oncology - Tập 30 - Trang v494 - 2019
H.J. Conter1, L.D. MacDonald2, S. Fiset2, Y.M. Bramhecha2, M. Chaney3, G.N. Rosu2
1Medical Oncology, William Osler Health System Foundation, Brampton, ON, Canada
2Clinical Research, IMV Inc., Dartmouth, NS, Canada
3Merck & Co., Inc., Kenilworth, NJ, USA

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 30

v494

Thông tin tác giả